Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial.
Balana C, De Las Penas R, Sepúlveda JM, Gil-Gil MJ, Luque R, Gallego O, Carrato C, Sanz C, Reynes G, Herrero A, Ramirez JL, Pérez-Segura P, Berrocal A, Vieitez JM, Garcia A, Vazquez-Estevez S, Peralta S, Fernandez I, Henriquez I, Martinez-Garcia M, De la Cruz JJ, Capellades J, Giner P, Villà S. Balana C, et al. J Neurooncol. 2016 May;127(3):569-79. doi: 10.1007/s11060-016-2065-5. Epub 2016 Feb 3. J Neurooncol. 2016. PMID: 26847813 Clinical Trial.
Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with renal cell carcinoma.
García Del Muro X, Gallardo E, García Carbonero I, Laínez N, José Méndez M, Maroto P, Ochoa de Olza M, Puente J, Reynes G, Rubio J, Santander C, Suárez C, Vázquez Estévez S, Castellano D. García Del Muro X, et al. Cancer Chemother Pharmacol. 2014 Jun;73(6):1095-107. doi: 10.1007/s00280-014-2413-0. Epub 2014 Feb 16. Cancer Chemother Pharmacol. 2014. PMID: 24531612 Review.
Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL).
Garcia-Campelo R, Arrieta O, Massuti B, Rodriguez-Abreu D, Granados ALO, Majem M, Vicente D, Lianes P, Bosch-Barrera J, Insa A, Dómine M, Reguart N, Guirado M, Sala MÁ, Vázquez-Estevez S, Caro RB, Drozdowskyj A, Verdú A, Karachaliou N, Molina-Vila MA, Rosell R; Spanish Lung Cancer Group (SLCG). Garcia-Campelo R, et al. Lung Cancer. 2020 Dec;150:62-69. doi: 10.1016/j.lungcan.2020.09.018. Epub 2020 Oct 3. Lung Cancer. 2020. PMID: 33070053 Clinical Trial.
Randomized phase 3 noninferiority trial of radiotherapy and cisplatin vs radiotherapy and cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer.
Hitt R, Mesía R, Lozano A, Iglesias Docampo L, Grau JJ, Taberna M, Rubió-Casadevall J, Martínez-Trufero J, Morillo EDB, García Girón C, Vázquez Estévez S, Cirauqui B, Cruz-Hernández JJ. Hitt R, et al. Oral Oncol. 2022 Nov;134:106087. doi: 10.1016/j.oraloncology.2022.106087. Epub 2022 Sep 18. Oral Oncol. 2022. PMID: 36126605 Clinical Trial.
Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO study.
Pérez-Valderrama B, Arranz Arija JA, Rodríguez Sánchez A, Pinto Marín A, Borrega García P, Castellano Gaunas DE, Rubio Romero G, Maximiano Alonso C, Villa Guzmán JC, Puertas Álvarez JL, Chirivella González I, Méndez Vidal MJ, Juan Fita MJ, León-Mateos L, Lázaro Quintela M, García Domínguez R, Jurado García JM, Vélez de Mendizábal E, Lambea Sorrosal JJ, García Carbonero I, González del Alba A, Suárez Rodríguez C, Jiménez Gallego P, Meana García JA, García Marrero RD, Gajate Borau P, Santander Lobera C, Molins Palau C, López Brea M, Fernández Parra EM, Reig Torras O, Basterretxea Badiola L, Vázquez Estévez S, González Larriba JL. Pérez-Valderrama B, et al. Ann Oncol. 2016 Apr;27(4):706-11. doi: 10.1093/annonc/mdv601. Epub 2015 Dec 9. Ann Oncol. 2016. PMID: 26658889 Free article. Clinical Trial.
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.
Conteduca V, Wetterskog D, Sharabiani MTA, Grande E, Fernandez-Perez MP, Jayaram A, Salvi S, Castellano D, Romanel A, Lolli C, Casadio V, Gurioli G, Amadori D, Font A, Vazquez-Estevez S, González Del Alba A, Mellado B, Fernandez-Calvo O, Méndez-Vidal MJ, Climent MA, Duran I, Gallardo E, Rodriguez A, Santander C, Sáez MI, Puente J, Gasi Tandefelt D, Wingate A, Dearnaley D; PREMIERE Collaborators; Spanish Oncology Genitourinary Group; Demichelis F, De Giorgi U, Gonzalez-Billalabeitia E, Attard G. Conteduca V, et al. Ann Oncol. 2017 Jul 1;28(7):1508-1516. doi: 10.1093/annonc/mdx155. Ann Oncol. 2017. PMID: 28472366 Free PMC article. Clinical Trial.
Concurrent chemoradiation for locally advanced stage III non-small cell lung cancer with cisplatin, vinorelbine, and thoracic radiotherapy: a phase II study from the Galician Lung Cancer Group.
Costa Rivas M, Huidobro Vence G, Fírvida Pérez JL, Campos Balea B, García Gonzalez J, Lázaro Quintela M, Caeiro Muñoz M, Taboada Valladares B, Castro Gómez JE, Vázquez Estevez S, Afonso Afonso FJ, Azpitarte Raposeiras C, Amenedo Gancedo M, Casal Rubio J. Costa Rivas M, et al. Clin Transl Oncol. 2018 Nov;20(11):1467-1473. doi: 10.1007/s12094-018-1880-x. Epub 2018 Apr 25. Clin Transl Oncol. 2018. PMID: 29696478 Clinical Trial.
47 results